NCT06114108Recruiting
Trial Comparing Systemic Therapy Alone and With Local Ablative Treatment for Stage IV NSCL Cancer Patients
Phase III Randomized Controlled Trial Comparing Maintenance Systemic Therapy Alone With Systemic Therapy Plus Local Ablative Treatment for Patients With Advanced Stage IV Non-small Cell Lung Cancer
Source: ClinicalTrials.gov · Last updated 2 Apr 2026
Brief summary (registry, in English)
Unfortunately, most patients are already at a very advanced stage when they are diagnosed with lung cancer, i.e. the cancer has already spread outside the lungs forming metastases. The current standard of care therapy at this advanced stage of lung cancer includes systemic anti-cancer therapy such as chemotherapy, immunotherapy to boost the body's immune response, or targeted therapy that directly hinders tumor growth. In this study, the aim is to find out whether it is better if, after a good response to the standard therapy, the remains of main tumor and the metastases are additionally treated by surgery and/or radiation.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 128 (estimated)
- First submitted
- 22 Sept 2023
- Start date
- 21 Dec 2023
- Primary completion date
- 1 Nov 2027
- Lead sponsor
- Swiss Cancer Institute
- Diseases
- Lung cancer
- NCT number
- NCT06114108
What you commit to
- Study type: Interventional
- Planned participants: 128
- From 21 Dec 2023 to the primary completion date, 1 Nov 2027
- 7 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Serious concomitant disorder that would compromise patient safety during LAT
Other illness
- Metastatic locations such as malignant ascites, malignant pleural or malignant pericardial effusion, diffuse lymphangiosis of skin or lung, diffuse bone marrow metastasis, abdominal masses/abdominal organomegaly, identified by physical exam that is not measurable by reproducible imaging techniques, leptomeningeal carcinomatosis
Other
- The presence of any one of the following exclusion criteria at screening will lead to exclusion of the participant:
- Unresolved complications from initial systemic anticancer treatment, higher than CTCAE grade 2
- Women who are pregnant or breast feeding
- Patient is currently involved in a trial that either does not permit participation in other trials or would result in excessive patient burden if another trial were joined. In such cases, the co-investigators' team and the Patient Advisory Board will decide on participation on an individual basis.
Who the study is looking for
- Patients fulfilling all of the following inclusion criteria at screening may be enrolled in the trial.
- The inclusion criteria are irrespective from the tumor burden at the time of primary diagnosis before initiation of first line systemic therapy. Treatment of brain metastases upfront or after an induction phase of standard systemic therapy is done according to the standard practice of the treating center.
- Adults (18 years or older)
- Tissue confirmed, pre-treatment clinical stage IV NSCLC
- ECOG performance status ≤ 1
- Patients responding after 3 cycles (4th bridging cycle up until randomization is allowed) or 3 months of first line SoC systemic therapy with PR or SD in restaging imaging, and presenting with (induced) oligometastatic or oligopersistent NSCLC defined as a maximum of 5 residual extracranial, distant metastases
- Patients may have up to 5 cranial metastases in addition to the oligoresidual extracranial metastases as long as they are amenable for radiotherapy or surgery.
- The primary tumor and all oligopersistent metastases must be amenable for radical LAT (surgery or radiotherapy)
- Patients of reproductive age agree to use double contraception during the study
- Patient is able to understand trial procedures and is able/willing to adhere to trial procedures as confirmed by signature
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (7)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Kantonspital Aarau Coordinator of this site? Confirm its status | Aarau | Switzerland | Recruiting |
| IOSI Ospedale Regionale di Bellinzona e Valli Coordinator of this site? Confirm its status | Bellinzona | Switzerland | Recruiting |
| Kantonsspital Graubuenden Coordinator of this site? Confirm its status | Chur | Switzerland | Recruiting |
| Hôpital Fribourgeois - Hôpital Cantonal Coordinator of this site? Confirm its status | Fribourg | Switzerland | Recruiting |
| Hôpitaux Universitaires Genève HUG Coordinator of this site? Confirm its status | Geneva | Switzerland | Recruiting |
| Luzerner Kantonsspital Coordinator of this site? Confirm its status | Lucerne | Switzerland | Recruiting |
| Universitätsspital Zürich Coordinator of this site? Confirm its status | Zurich | Switzerland | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.